What the 70–85% success figure actually means

Seventy to eighty-five per cent — that figure appears in virtually every published summary of ChondroFiller outcomes, and it is worth understanding precisely what it does and does not mean before drawing any conclusions about suitability.

The number represents the proportion of appropriately selected patients who achieve significant symptom relief — defined in the clinical literature as a meaningful reduction in pain and a measurable improvement in joint function that clears the minimum clinically important difference (MCID) on validated outcome scales. In the knee, for example, the primary measure is the International Knee Documentation Committee (IKDC) score, where the MCID sits at 16.7 points; across published European cohorts, ChondroFiller-treated patients average a 30-point gain. That is roughly double the threshold for a result the patient would notice in daily life. Hip studies use the Harris Hip Score, and MRI-based MOCART scores — ranging from 81.6 to 84.3 in European studies — provide an independent structural check that goes beyond what patients self-report.

This consistency holds across joint types and research groups. The 70–85% range has been reported in knee, hip, and small-joint cohorts from independent centres, not a single clinic's data.

ChondroFiller itself is a CE-marked Class III acellular Type I collagen hydrogel scaffold. Delivered as an ultrasound-guided outpatient injection into a focal cartilage defect, it works by providing a structural matrix that recruits the patient's own progenitor cells — a process known as acellular matrix-induced chondrogenesis — rather than introducing live cells or acting as a simple lubricant.

The 70–85% range is real, but it is not fixed. Where an individual sits within it depends largely on patient selection — the single greatest predictor of outcome, and the subject examined in detail later in this article.

Knee evidence: what IKDC scores and MRI show

Four independent clinical studies examining the knee have arrived at essentially the same functional result — an IKDC score improvement of approximately 30 points — across different research groups and study designs. That degree of convergence, using the same validated outcome measure, carries more weight than any single cohort result. The longest data set comes from the Jerosch et al. post-market clinical follow-up (PMCF) study, which recorded a mean gain of 32.4 points, lifting patients to a functional IKDC score of 80, with that result sustained and marginally higher at three-year review.

A 2024 Bulgarian knee cohort (n=17, mean age 31) adds a useful timing dimension. Lysholm and IKDC scores improved significantly at three, six, and twelve months post-injection (p<0.05 at each time point), but there was no statistically significant difference between the six-month and twelve-month readings. That plateau suggests the bulk of functional recovery consolidates within the first half-year after the collagen scaffold is placed — a clinically useful anchor when discussing post-treatment expectations.

Structural recovery follows a different arc, and the distinction matters for return-to-activity planning. MRI MOCART scores measure cartilage fill quality, tissue integration, and surface congruity — what the scaffold is building rather than what the patient subjectively feels. In the 2016 randomised multi-centre study (n=23), MOCART scores progressed from 65.3 at four weeks to 81.6 at one year, a steady maturation signal that outlasts the functional improvement window by several months. Across European cohorts, MOCART scores consistently reach 81.6–84.3 at one year, indicating good-to-excellent cartilage fill on imaging.

The practical implication is that two timelines run in parallel: patients typically notice most of the functional benefit by six months, while the structural repair documented on MRI continues to consolidate well beyond that point.

Hip and small-joint outcomes beyond the knee

Beyond the knee, the published evidence covers two further joint territories with meaningful follow-up data — and both extend the 70–85% success pattern into different anatomical contexts.

Hip. The most substantial non-knee dataset comes from Mazek et al. (2021), a prospective cohort of 26 adults with acetabular cartilage lesions greater than 2 cm², followed for 12 to 60 months. Of the 21 evaluable patients, 17 (81%) achieved good or excellent outcomes at the 3–5 year mark, and Harris Hip Score improvements of approximately +33 points have been reported across the hip evidence base — matching the functional magnitude recorded in knee studies. That 3–5 year follow-up window is the longest in the published ChondroFiller record, lending the hip cohort a durability argument that the knee data, to date, does not fully replicate. An earlier 2016 randomised multi-centre study (n=23) confirmed the technique was 'safe and simple' with all cartilage defects successfully filled on MRI; however, high dropout in the microfracture comparator arm (six of ten patients declined surgery) prevented any head-to-head statistical conclusion. That study's contribution is confirmatory safety rather than comparative efficacy.

Wrist. Demmer et al. (2025; n=25) extended the scaffold principle into small-joint repair, treating chondral defects following intra-articular distal radius fractures. Follow-up arthroscopy demonstrated significantly better cartilage quality in the ChondroFiller group versus untreated controls — median Outerbridge grade 1.5 versus 3 (P=0.006) and ICRS grade 1 versus 3 (P=0.002). One technique observation is clinically relevant: fibrous tissue formation occurred exclusively in overfilled defects; applications placed flush with the articular surface were free of it. Both cohorts are smaller than the knee series, but the pattern of scaffold-driven repair — and its sensitivity to precise placement — holds consistently across joint types.

Who is and isn't a good candidate

Not every patient with a damaged joint is a candidate — and the published evidence is unusually clear about who benefits and who does not.

The most decisive selection factor is the degree of background osteoarthritis. Across cohort studies, patients graded Tönnis 2–3 (hip) or Kellgren–Lawrence III–IV (knee) — both indicating moderate-to-advanced joint degeneration — consistently show poor outcomes. The reason is structural: ChondroFiller is designed to restore focal, isolated cartilage defects in an otherwise serviceable joint. Where surrounding cartilage is already substantially degraded, the biological environment that normally supports scaffold integration and cell recruitment is compromised. This distinction — a discrete focal defect versus widespread degenerative disease — is the single most important filter in any pre-treatment assessment.

Defect geometry matters alongside OA grading. The Mazek et al. (2021) hip cohort enrolled patients with acetabular lesions greater than 2 cm², and the Demmer et al. (2025) wrist study focused on discrete chondral injuries from intra-articular fractures — both examples of bounded, focal pathology, not diffuse joint wear.

Post-procedure compliance is equally consequential. A 2024 biomechanical in-vitro study (porcine model, cyclic loading) found that in the early period after scaffold placement, ChondroFiller does not shield the opposing cartilage surface from loading stress, because the gel has not yet achieved mechanical stability within the defect. The recommendation to delay full weight-bearing until stable integration is confirmed follows directly from that finding — it is the scaffold's maturation biology, not an arbitrary restriction.

The headline 70–85% success figure that runs through the published cohorts applies to appropriately selected patients. Pre-treatment assessment — covering OA grade, defect size and location, overall joint condition, and the patient's capacity to observe post-injection guidance — is what determines whether an individual is likely to sit within that range.

The biological mechanism behind the outcomes

Understanding why the outcomes look the way they do starts with what the scaffold itself contains — which is nothing living. ChondroFiller is an acellular Type I collagen hydrogel: no cells are delivered with it. Instead, the gel creates a three-dimensional matrix that invites the patient's own progenitor cells — recruited from the surrounding synovium and underlying subchondral bone — to migrate in and begin repair. This process is termed acellular matrix-induced chondrogenesis.

The clearest biological confirmation of that mechanism comes from a 2025 ex vivo osteochondral explant study, which measured a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14. DNA accumulation at that scale, in the absence of any seeded cells, points directly to host-cell infiltration into the scaffold — precisely the migration event the mechanism predicts.

The same study tested what happens when mesenchymal stem cells (MSCs) are co-delivered alongside the scaffold. The result was further augmentation of both collagen deposition and glycosaminoglycan (GAG) production — the two structural proteins that give healthy cartilage its load-bearing properties. This is the biological rationale behind combining the scaffold with autologous cell therapies in cases where the defect size or complexity warrants additional support. It should be noted, however, that published clinical trial data for the combined scaffold-plus-MSC protocol as a single pathway do not yet exist; the mechanistic case is established, but the clinical evidence base for that combination remains to be built.

This biology also explains the MRI maturation pattern noted in imaging studies — cartilage repair is a cellular process measured in months, not days, and the scaffold simply creates conditions for it to proceed.

Where the evidence still has gaps

The published evidence is broadly consistent — but it has defined edges, and patients deserve to know where those edges sit.

The most significant gap is comparative: no adequately powered, multi-centre randomised controlled trial has yet placed ChondroFiller directly against microfracture or autologous chondrocyte implantation (ACI) in a head-to-head design with sufficient follow-up to draw firm conclusions. The 2016 trial (n=23) remains the only randomised study, and its microfracture comparator arm suffered such high dropout — six of ten patients declined surgery — that no statistical comparison was possible. That single study confirmed safety and feasibility; it did not settle the comparative-efficacy question.

Long-term durability data have a similar boundary. The hip cohort from Mazek et al. (2021) provides follow-up out to five years. Knee data, including the Jerosch et al. PMCF study, extend to three years. What happens beyond those windows in either joint is not yet published.

The underlying evidence base is composed primarily of small European prospective cohorts, several of which are manufacturer-associated PMCF studies. Independent, large-scale replication at centres unaffiliated with product development remains sparse — a standard limitation of the early post-market phase for any CE-marked Class III device, but one worth naming plainly.

Finally, the Liquid Cartilage Surgery protocol — combining the collagen scaffold with co-injected autologous MSCs — rests on well-established mechanistic data, as the 2025 ex vivo study demonstrated. Dedicated clinical outcome data for the combined pathway as a single protocol do not yet exist.

None of these gaps invalidate the existing evidence. They describe where the science currently stands and where further research is most needed. For an individual patient, this is precisely why the published cohort figures are a starting point rather than a personal forecast — and why a consultant-led assessment of defect characteristics, joint condition, and overall health context remains essential before any treatment decision is reached.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up (Mazek et al., 2021). (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8460160/ https://pmc.ncbi.nlm.nih.gov/articles/PMC8460160/
2. [2] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint (2024). (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee (2016). (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures (Demmer et al., 2025). (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12498443/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12498443/
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration (2025). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study (2024). (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z